Premium
Pacemaker and Implantable Cardioverter Defibrillator Implantation Without Reversal of Warfarin Therapy
Author(s) -
GIUDICI MICHAEL C.,
BAROLD S. SERGE,
PAUL DEBORAH L.,
BONTU PRAVEEN
Publication year - 2004
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.2004.00441.x
Subject(s) - medicine , implantable cardioverter defibrillator , percutaneous , permanent pacemaker , cardiology , complication , warfarin , surgery , artificial cardiac pacemaker , atrial fibrillation
The study evaluated all patients undergoing permanent pacemaker and ICD implantation over a 4‐year period to determine if anticoagulated patients required normalization of coagulation factors in the periprocedural period. The study included 1,025 (597 men, 428 women, age 24–100 years, mean 72 years) consecutive patients who underwent device implantation using mostly a percutaneous subclavian approach. The procedures were performed without reversal of anticoagulation in 470 patients with INRs ≥ 1.5 at the time of the procedure (mean INR 2.6 ± 1.0, range 1.5–7.5). The complication rate in the anticoagulated group was similar to those in patients with a normal INR. Routine normalization of coagulation factors prior to pacemaker/ICD placement may not be necessary. (PACE 2004; 27:358–360)